Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David McConkey

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Blood|July 24, 2010
Proteasome and HDAC: who's zooming who?David McConkey
European Urology|November 28, 2017
Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65Woonyoung Choi, David McConkey
Annual Review of Pathology|February 25, 2016
Origins of Bladder CancerBogdan Czerniak, Colin Dinney, David McConkey
European Urology Oncology|August 7, 2019
Does it matter whether a T1 high-grade tumor is molecularly classified?Arnulf Stenzl, David McConkey, Joaquim Bellmunt
European Urology|September 10, 2014
Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjödahl, and Mattias Höglund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 2014;66:609-10David McConkey, Woonyoung Choi, Colin Dinney
Cancer Biology & Therapy|May 24, 2005
Velcade displays promising activity in primary effusion lymphoma cellsDavid McConkey, Steffan T Nawrocki, Robert Andtbacka
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
What is a Bladder Cancer Molecular Subtype? - CounterpointFrançois Radvanyi, Francisco X Real, David McConkey
European Urology Oncology|August 10, 2019
Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?Maximilian Burger, Ashish M Kamat, David McConkey
Bladder Cancer (Amsterdam, Netherlands)|August 12, 2024
The Evolution of Nadofaragene Firadenovec: A Review and the Path ForwardAlexis R Steinmetz, Sharada Mokkapati, David McConkey, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 8, 2020
Renal Cell and Urothelial Carcinoma: Biomarkers for New TreatmentsAndrew L Schmidt, Arlene Siefker-Radtke, David McConkey, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Blood|July 24, 2010
Proteasome and HDAC: who's zooming who?David McConkey
European Urology|November 28, 2017
Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354-65Woonyoung Choi, David McConkey
Annual Review of Pathology|February 25, 2016
Origins of Bladder CancerBogdan Czerniak, Colin Dinney, David McConkey
European Urology Oncology|August 7, 2019
Does it matter whether a T1 high-grade tumor is molecularly classified?Arnulf Stenzl, David McConkey, Joaquim Bellmunt
European Urology|September 10, 2014
Reply to Mattias Aine, Fredrik Liedberg, Gottfrid Sjödahl, and Mattias Höglund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New insights into subtypes of invasive bladder cancer: considerations of the clinician. Eur Urol 2014;66:609-10David McConkey, Woonyoung Choi, Colin Dinney
Cancer Biology & Therapy|May 24, 2005
Velcade displays promising activity in primary effusion lymphoma cellsDavid McConkey, Steffan T Nawrocki, Robert Andtbacka
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
What is a Bladder Cancer Molecular Subtype? - CounterpointFrançois Radvanyi, Francisco X Real, David McConkey
European Urology Oncology|August 10, 2019
Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?Maximilian Burger, Ashish M Kamat, David McConkey
Bladder Cancer (Amsterdam, Netherlands)|August 12, 2024
The Evolution of Nadofaragene Firadenovec: A Review and the Path ForwardAlexis R Steinmetz, Sharada Mokkapati, David McConkey, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 8, 2020
Renal Cell and Urothelial Carcinoma: Biomarkers for New TreatmentsAndrew L Schmidt, Arlene Siefker-Radtke, David McConkey, et al.
Pageof 8